Our Focus
Discover more about cisplatin-induced hearing loss and read our latest work on the subject
Fennec Supported Clinical Trials
Compassionate Use Program (Turkey): newly diagnosed hepatoblastoma
- Start date: Oct 21, 2019
- Duration: 3 years accrual + 1 year follow-up
- NCT number: NCT04132822
ACNS2031: COG study: newly diagnosed average risk medulloblastoma
- Start date: July 1, 2022
- Duration: 4.5 years accrual + 3 years follow-up
- NCT number: NCT05382338
STS J-01: Hiroshima University: newly diagnosed solid tumors
- Start date: June 1, 2022
- Duration: 3 years + 1 year of follow-up
- JRCT number: jRCT2061220018